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Abstract
Purpose Liposomal cisplatin was developed to reduce the
systemic toxicity of cisplatin, particularly the nephrotoxi-
city, and it has been used in combination with other agents
in pancreatic and head and neck cancers and non-small-cell
lung cancer (NSCLC). Our objective was to compare the
effectiveness of lipoplatin combined with paclitaxel versus
cisplatin with paclitaxel in advanced non-squamous
NSCLC.
Methods During 2007–2010, 202 patients with non-squa-
mous NSCLC (stage IIIB and IV) were recruited from the
twoparticipatinginstitutionsanddividedintotwoarms:Arm
Awastreatedwithliposomalcisplatin200 mg/m
2combined
with paclitaxel 135 mg/m
2and Arm Bwith cisplatin 75 mg/
m
2 in combination with paclitaxel 135 mg/m
2, repeated
every 2 weeks. The number of cycles administered was 632
(Arm A) and 640 (Arm B), totaling 1,272.
Results A partial response was achieved by 59.22% of
Arm A patients versus 42.42% of Arm B, and the differ-
ence was statistically signiﬁcant (P 0.036). The median
survival time in months was 10 for Arm A and 8 for Arm B
(P 0.1551). After 18 months, the number of surviving
patients was double for Arm A versus Arm B.
Conclusion Liposomal cisplatin in combination with
paclitaxel produces a statistically signiﬁcantly higher
response rate than cisplatin combined with paclitaxel in
non-squamous NSCLC.
Keywords Liposomal cisplatin  Non-squamous cell
carcinoma
Introduction
Over the last three decades, cisplatin (CDDP) has been one
of the most effective cytotoxic drugs. Carcinomas of the
head and neck, bladder, testicles, ovaries, esophagus, and
lung are the most common malignancies that are sensitive
to cisplatin when combined with a second or third cyto-
toxic agent [1–5]. Cisplatin has provided a survival
advantage and a higher response rate, but its major problem
has been toxicity, particularly nephrotoxicity [6, 7]. Over
the years, attempts were made to ﬁnd a substitute for cis-
platin, mainly in the use of its analogue, carboplatin [5, 8].
Other cytotoxic agents such as taxanes (paclitaxel, doce-
taxel), gemcitabine, vinorelbine, pemetrexed, and irino-
tecan have also been used as substitutes [9–11]. However,
none of these agents has proved to be superior to CDDP in
effectiveness. Liposomal cisplatin (Lipoplatin, Regulon
Inc., Mountain View, California) is another agent whose
use over the last few years has been ongoing in trials.
Lipoplatin is a new liposomal formulation formed from
cisplatin and liposomes composed of dipalmitoyl phospha-
tidyl glycerol (DPPG), soyphosphatidyl choline (SPC-3),
cholesterol, and methoxypolythylene glycol-distearoyl
phosphatidylethanolamine (m-PEG 2000-DSPE). It was
developed to reduce the systemic toxicity of cisplatin while
attemptingtoimprovethetargetingofthedrugtotheprimary
tumor and to metastases by enhancing the half-life circula-
tion time in body ﬂuids and tissues. Preclinical studies have
shown lipoplatin’s lower toxicity inrats, in comparison with
cisplatin [12, 13]. Two phase I studies have tested lipopla-
tin’s pharmacokinetic proﬁle and adverse reactions [14] and
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DOI 10.1007/s00280-011-1572-5preferential tumor uptake in human studies [15]. Lipoplatin
is administered in 1L 5% dextrose for an 8-hour infusion.
The highest plasma concentration was deﬁned at 6 h, and
the platinum plasma levels were completely excreted after
4–7 days, the difference depending on the dosage of li-
poplatin [14]. In a phase I–II trial, lipoplatin was combined
with gemcitabine in patients with advanced pancreatic can-
cer; doses higher than 100–150 mg/m
2 were well tolerated,
and the only adverse reaction was grade 1–2 myelotoxicity
[16]. Other trials have shown low or negligible nephrotoxi-
city [14, 17]. As monotherapy, lipoplatin is tolerated at a
level of 350 mg/m
2 [18]. Lipoplatin treatment of non-small-
cell lung cancer (NSCLC) was tested in two randomized
trials,aphaseIIandaphaseIII[19,20].Itwasfoundthatthe
combination of lipoplatin with gemcitabine or with paclit-
axel showed effectiveness similar to cisplatin plus gemcit-
abine or paclitaxel, but that there was much less toxicity
with the lipoplatin combination.We alsoobservedthat there
was a difference in the response rate of patients with
non-squamous NSCLC,and this was an indicationto run the
present trial.
The aim of the present study was to evaluate the com-
parison between lipoplatin and cisplatin combinations with
respect to response rate and median and overall survival in
patients with non-squamous NSCLC.
Materials and methods
Patients’ eligibility
Eligibility for the study required histologically or cytolog-
ically conﬁrmed NSCLC patients who were chemotherapy-
and radiotherapy-naı ¨ve, classiﬁed as stage IIIB and IV and
considered inoperable. Patients who had bidimensionally
measurable disease on physical examination, X-rays,
computed tomography (CT), WHO performance status (PS)
of 0–2, expected survival C12 weeks, adequate bone mar-
row reserves (leukocyte count C3,500 ll
-1, platelet count
C100,000 ll
-1, and hemoglobin C10 g ll
-1), adequate
renal function (serum creatinine B1.5 mg dl
-1) and liver
function (serum bilirubin not more than 1.5 mg dl
-1 and
serum transaminases not more than three times the upper
limit of normal or not more than ﬁve times the upper limit of
normal in cases of liver metastases), and age at least
18 years were eligible. In cases of central nervous system
(CNS) involvement, patients were excluded unless they
were asymptomatic. Patients with a second malignancy
were also excluded. The study was conducted in accordance
with the Declaration of Helsinki and Good Clinical Practice
Guidelines [21] and was approved by both participating
hospital institutional ethics review boards. All patients gave
their informed consent before entering the study.
Study design
The study was designed as a double-center phase III
randomized trial. It was powered to detect a difference
in the response rate and survival between the two arms.
The sample was initially planned to include 200 patients
(100 in each arm) with an increase in the number of
patients if a statistical difference of 5% between the two
arms, with regard to the response rate and to the median
survival, was not reached. The randomization was per-
formed centrally, and patients were stratiﬁed by three
prognostic variables: disease stage (locally advanced
versus metastatic disease), WHO PS of 0–2, and inves-
tigational site.
Statistical design
Patients were randomly assigned to the two treatment arms:
Arm A was treated with lipoplatin plus paclitaxel and Arm
B, cisplatin plus paclitaxel. Randomization was performed
according to the method of random permuted blocks within
strata. The stratiﬁcation factor comprised disease stages
IIIB and IV. Dynamic balancing by center was also per-
formed. For time to disease progression and overall sur-
vival, the Kaplan–Meier method was used to estimate
survival distribution and the log-rank test for the compar-
ison of the treatment arms.
The response rates of the two treatment arms were
calculated by the x
2 test or Fisher’s exact test, when
appropriate. The Mann–Whitney U test was used for tox-
icity-grade comparisons. All tests were two-sided. A
P value less than 0.05 (Pearson’s chi-square test) was
considered signiﬁcant. The duration of response was cal-
culated from the day of the ﬁrst demonstration of response
until PD. Progression-free survival (PFS) was calculated
from the day of entry into the study until documented PD.
Overall survival (OS) was calculated from the day of
enrollment until death, or to the end of the study.
Treatment plan
Patients were randomly assigned to Arm A or Arm B.
Arm A patients were to be treated with lipoplatin
200 mg/m
2 in combination with paclitaxel 135 mg/m
2.
Lipoplatin was infused in 1L 5% dextrose for 8 h,
without an extra infusion for hydration. Paclitaxel, given
before lipoplatin, was infused for 3 h. Arm B patients
were also given paclitaxel 135 mg/m
2 for 3 h and cis-
platin 75 mg/m
2 in 250 ml normal saline solution
accompanied by 1L 5% dextrose and 1L electrolyte.
Premedication included ondansetron 8 mg intravenously
(IV), dexamethasone 8 mg IV, and diphenyldramine
50 mg IV with modiﬁed timing 1 h before the beginning
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123of treatment and repeated 4 and 8 h thereafter. Treatment
of both arms was repeated every 2 weeks; this every
2-week treatment has been tested in other trials [22–24].
Nine cycles were planned. In repeating the treatment
every 2 weeks, the dosages of cisplatin and paclitaxel
were reduced to 75 mg/m
2 instead of 100 mg/m
2 for the
former and 135 mg/m
2 instead of 175 mg/m
2 for the
latter. Patients who responded to treatment continued to
the end of the planned number of courses. Course delays
of 1 week were permitted for recovery from adverse
reactions. Concomitant supportive therapies, such as
granulocyte colony-stimulating factors or blood transfu-
sions, antibiotics and erythropoietic agents were allowed
according to the ASCO guidelines [25].
Baseline and treatment assessment/evaluation
Before study entry, all patients underwent the following
evaluations: medical history, physical examination, tumor
measurement or evaluation, WHO PS, ECG, full blood
count, liver and kidney function tests, and urinalysis.
Staging was determined by chest and abdominal com-
puted tomography, bone scan, and occasionally magnetic
resonance imaging. Blood count, blood urea, and serum
creatinine were measured before each treatment admin-
istration and 7 days after each course. During the treat-
ment period, radiologic tests were conducted after four
courses, at the end of the study and after any course if
the clinical signs were indicative of disease progression.
Disease status was assessed according to the response
evaluation criteria in solid tumors. Randomly assigned
patients who met the eligibility criteria were assessable
for tumor response and duration of response. All patients
in both arms who received at least one course of treat-
ment were considered assessable for safety. Patients
were assessed for toxicity according to the National
Cancer Institute Common Toxicity Criteria, version 2.0.
A complete response (CR) was considered to be the
disappearance of all measurable disease conﬁrmed at
4 weeks at the earliest; a partial response (PR), a 30%
decrease in all measurable disease, also conﬁrmed at
4 weeks at the earliest. In stable disease (SD), neither
PR nor the progressive disease (PD) criteria were met;
PD was considered to be a 20% increase in tumor bur-
den and no CR, PR, or SD documented before increased
disease [26]. A two-step deterioration in PS, a more than
10% loss of pretreatment weight, or increasing symptoms
did not by themselves constitute progression of the dis-
ease; however, the appearance of these complaints was
followed by a new evaluation of the extent of the dis-
ease. All responses had to be maintained for at least
4 weeks and be conﬁrmed by an independent panel of
radiologists and oncologists.
Results
From September 2007 until February 2010, 202 patients
were enrolled in this double-center trial. All 202 patients
(103 in Arm A and 99 in Arm B) were evaluable for
response rate, survival, and toxicity. The patients’ charac-
teristics are shown in Table 1; gender, age, PS, and histo-
logical or cytological examination are presented for both
arms. The two arms of the study were well balanced with
respect to the total number of patients and the aforemen-
tioned parameters.
Response evaluation
The response rate is shown in Table 2. No complete
response was achieved in either of the two arms. In Arm A,
partial remission was determined in 61/103 (59.22%)
patients, stable disease in 35 (33.98%), and disease pro-
gression in 7 (6.80%). In Arm B, 42/99 (42.42%) patients
achieved partial remission, 43 (43.43%) stable disease, and
disease progression was determined in 14 (14.14%). There
was a statistically signiﬁcant difference in the response rate
between the two arms in favor of Arm A (P 0.036,
Table 2). No statistically signiﬁcant difference with regard
Table 1 Patient characteristics at baseline
Arm A,
Arm B
Arm A
n (%)
Arm B
n (%)
Total
No. of patients treated 103 99 202
Gender
Male 89 (86.41) 76 (76.77)
Female 14 (13.59) 23 (23.23)
Age (year)
Median 65, 65
Range 37–78, 41–82
WHO PS
0 21 (20.39) 16 (16.16)
1 66 (64.08) 63 (63.64)
2 16 (15.53) 20 (20.20)
Histology (cytology)
Non-squamous cell carcinoma
Adenocarcinoma 61 (59.22) 60 (60.61)
Undifferentiated 42 (40.78) 39 (39.39)
Disease stage
IIIB 56 (54.37) 56 (56.57)
IV 47 (45.63) 43 (43.43)
Stage IV
Liver 23 (48.94) 21 (48.84)
Bone 11 (23.40) 10 (23.26)
Adrenal 3 (6.38) 4 (9.30)
Multiple sites 10 (21.28) 8 (18.60)
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123to age, gender, and tumor differentiation per arm was
determined. The median duration of response for Arm A
was 7 months (95% CI 4.6–9.4) and for Arm B, 6 months
(95% CI 4.2–7.8). After the 10th month, there was a
superiority in the survival rate in Arm A where 30% of the
patients were without disease progression whereas in Arm
B this was 16%.
Survival time to event
The median follow-up time was 18 months. The study
ended in February 2010; by the end of the trial, there were
32 patients alive, 21 from Arm A (28.39%) and 11 from
Arm B (11.11%).
The median survival time for Arm A patients was
10 months (CI 95% 6.6–13.4) and for Arm B, 8 months
(95% CI 5.4–10.6) (Fig. 1). No statistically signiﬁcant
difference was determined between the two arms (log-rank
test P value 0.1551, Table 3). According to the statistics,
the cumulative survival of 20 months in Arm A was 0.23
and in Arm B, 0.16.
Toxicity
Adverse reactions were mainly observed in Arm B patients
treated with cisplatin–paclitaxel. In both arms, peripheral
neuropathy was observed; it was more common in Arm B,
but not signiﬁcant. A statistically signiﬁcant difference was
detected in nausea/vomiting, asthenia, and particularly in
nephrotoxicity (P\0.001). With regard to these three side
effects, less toxicity was observed in Arm A patients,
treated with liposomal cisplatin and paclitaxel. A detailed
toxicity analysis is reported in a previous trial [20]. There
were no deaths owing to treatment-related toxicity.
Discussion
In a previous trial, liposomal cisplatin was shown to be less
toxic than cisplatin when both were administered in com-
bination with paclitaxel [20]. The two main histological
types of NSCLC are squamous cell carcinoma and ade-
nocarcinoma. It is possible that the different histological
types of NSCLC do not have the same sensitivity to che-
motherapy. Past trials have pointed out that the squamous
cell type of lung cancer was more sensitive to chemo-
therapy than the adenocarcinoma cell type, with agents
including cisplatin. For quite a number of years, adeno-
carcinoma of the lungs was considered to be rather insen-
sitive to chemotherapy [9, 27, 28]. Past trials testing
chemotherapy for lung cancers did not classify the histo-
logical subtypes, and all lung carcinomas were categorized
as NSCLC for the treatment’s outcome [29–32]. Such
indications from previous trials led us to run the present
study where only patients with non-squamous NSCLC
were recruited; one group was treated with liposomal cis-
platin and the other with cisplatin, both combined with
paclitaxel.
The statistically signiﬁcant higher response rate of the
patients who received liposomal cisplatin versus cisplatin
in this study indicates that one should histologically sub-
divide the types of lung cancer by testing the response
magnitude of different cytotoxic combinations. Parameters
that are known and of importance in predicting the
response and survival of patients with NSCLC may be
tumor differentiation, disease stage and the site of the
metastasis. On the basis of published data, certain trials
have selected carboplatin as the platinum analogue of
choice for ﬁrst-line treatment of patients with metastatic
NSCLC to avoid nephrotoxicity [33]. Two phase III trials
comparing carboplatin plus paclitaxel with cisplatin-based
combinations demonstrated similar efﬁcacy, but lower
rates of nausea, leukopenia, and nephrotoxicity with the
use of carboplatin [9, 34].
Table 2 Response rate
Arm A
(n = 103)
Arm B
(n = 99)
P value
Partial response 61 (59.22%) 42 (42.42%) 0.036
Stable disease 35 (33.98%) 43 (43.43%) 0.220
Progressive disease 7 (6.80%) 14 (14.14%) 0.110
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Fig. 1 Kaplan–Meier median survival time
Table 3 Survival time (months), log-rank test P value = 0.1551
Arm n Median 95% CI
A 103 10.0 6.6–13.4
B 99 8.0 5.4–10.6
Total sample 202 9.0 6.8–11.2
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123Further clinical investigations comparing cisplatin ver-
sus carboplatin-based chemotherapy in the ﬁrst-line treat-
ment of advanced NSCLC are described in an individual
patient data meta-analysis. In nine trials, which included
2,968 patients, the response rate was higher for
patients treated with cisplatin than for patients treated with
carboplatin (30% vs. 24%, respectively, overall survival
P\0.001). Carboplatin was associated with a statistically
non-signiﬁcant increase in the hazard ratio, versus treat-
ment with cisplatin. These authors concluded that the
patient meta-analysis suggests that cisplatin-based chemo-
therapy is slightly superior to carboplatin-based chemo-
therapy in terms of response rate and in certain subgroups
[35]. Another comparison of chemotherapeutical agents in
NSCLC histological groups showed that pemetrexed was
more effective in adenocarcinoma and large-cell lung
cancer than in squamous cell carcinoma [36]. This latter
study was a retrospective analysis of a phase III trial
comparing pemetrexed versus docetaxel in a second-line
setting: the results indicated that patients treated with
docetaxel had a statistically signiﬁcant better survival rate
than those treated with pemetrexed in the squamous cell
subgroup, whereas pemetrexed rendered a statistically
signiﬁcant better survival rate in the non-squamous
subgroup.
These data plus the outcome of our trial suggest that
treatment selection of certain cytotoxic agents should be
deﬁned by the subtypes of NSCLC, thus resulting in a
better response rate and survival.
Liposomal cisplatin combined with paclitaxel showed a
statistically signiﬁcant higher response rate than cisplatin
combined with paclitaxel in the treatment of non-squamous
carcinomas of the lung.
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